RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Clinical trials for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-barreled cell therapy takes aim at hard-to-treat myeloma
Disease control Recruiting nowThis early-stage study tests a new treatment for people with advanced multiple myeloma that has spread outside the bones. The therapy uses a patient's own immune cells, modified to attack two cancer targets (BCMA and GPRC5D) at once. The main goal is to check safety in 18 adults,…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 17, 2026 05:09 UTC
-
New cell therapy aims to control Hard-to-Treat multiple myeloma
Disease control Recruiting nowThis study tests a new treatment called arlocabtagene autoleucel (a CAR-T cell therapy) for adults with multiple myeloma that has come back or not responded to prior treatments. The therapy uses a patient's own immune cells, modified to target cancer cells. The study compares thi…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated May 17, 2026 05:04 UTC
-
Double-Barreled cell therapy takes aim at Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage trial tests a new cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It is for people whose multiple myeloma has come back or stopped responding to treatment and has spread to other tissues. The main goal is to check the safety of this thera…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 14, 2026 12:05 UTC